Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | EPHA2 | P29317 | 13/20 | 0.81 |
| ▸ | USP2 | O75604 | 1/20 | 0.70 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.69 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.69 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.69 |
| ▸ | HIF1A | Q16665 | 1/20 | 0.69 |
| ▸ | GPBAR1 | Q8TDU6 | 2/20 | 0.68 |
| ▸ | VDR | P11473 | 1/20 | 0.68 |
| ▸ | TP53 | P04637 | 1/20 | 0.68 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.68 |
| ▸ | CASP7 | P55210 | 1/20 | 0.68 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.68 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL16464919 | 1.00 | EPHA2 (0.81) | EPHA2USP2CYP3A4CYP2C9CYP2C19 | |
| SCHEMBL27146330 | 0.91 | EPHA2 (0.85) | EPHA2USP2CYP3A4HIF1AGPBAR1 | |
| SCHEMBL8695656 | 0.91 | EPHA2 (0.85) | EPHA2USP2CYP3A4HIF1AGPBAR1 | |
| SCHEMBL8695653 | 0.91 | EPHA2 (0.85) | EPHA2USP2CYP3A4HIF1AGPBAR1 | |
| SCHEMBL16349395 | 0.90 | EPHA2 (0.84) | EPHA2USP2CYP3A4CYP2C9CYP2C19 | |
| SCHEMBL27130830 | 0.90 | EPHA2 (1.00) | EPHA2USP2CYP3A4CYP2C9CYP2C19 | |
| SCHEMBL27030912 | 0.90 | EPHA2 (1.00) | EPHA2USP2CYP3A4CYP2C9CYP2C19 | |
| SCHEMBL27044584 | 0.90 | EPHA2 (1.00) | EPHA2USP2CYP3A4CYP2C9CYP2C19 | |
| SCHEMBL27030902 | 0.89 | EPHA2 (0.82) | EPHA2USP2CYP3A4CYP2C9CYP2C19 | |
| SCHEMBL27149381 | 0.89 | EPHA2 (0.82) | EPHA2USP2CYP3A4CYP2C9CYP2C19 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 42 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2024003313-A1 | NEW PEPTIDES AS SELECTIVE IL-23 RECEPTOR ANTAGONISTS | SANOFI (FR) | 2024-01-04 | — | — | WO | claimed |
| EP-3400957-A1 | FUNCTIONALIZED EXENDIN-4 DERIVATIVES | Sanofi (FR) | 2018-11-14 | — | — | EP | claimed |
| EP-2934567-B9 | EXENDIN-4 DERIVATIVES AS DUAL GLP1/GIP- OR TRIGONAL GLP1/GIP/GLUCAGON AGONISTS | SANOFI SA (FR) | 2018-08-22 | — | — | EP | claimed |
| EP-2934567-B1 | EXENDIN-4 DERIVATIVES AS DUAL GLP1/GIP- OR TRIGONAL GLP1/GIP/GLUCAGON AGONISTS | SANOFI SA (FR) | 2018-05-09 | — | — | EP | claimed |
| EP-2934568-B1 | DUAL GLP1/GIP OR TRIGONAL GLP1/GIP/GLUCAGON AGONISTS | SANOFI SA (FR) | 2017-10-18 | — | — | EP | claimed |
| US-9745360-B2 | Dual GLP1/GIP or trigonal GLP1/GIP/glucagon agonists | SANOFI (FR) | 2017-08-29 | — | — | US | claimed |
| EP-2906595-B1 | EXENDIN-4 DERIVATIVES AS DUAL GLP1/GLUCAGON AGONISTS | SANOFI SA (FR) | 2017-08-16 | — | — | EP | claimed |
| US-20170216406-A1 | FUNCTIONALIZED EXENDIN-4 DERIVATIVES | SANOFI (FR) | 2017-08-03 | — | — | US | claimed |
| EP-2934566-B1 | EXENDIN-4 DERIVATIVES AS DUAL GLP1/GIP OR TRIGONAL GLP1/GIP/GLUCAGON AGONISTS | SANOFI SA (FR) | 2017-06-21 | — | — | EP | claimed |
| US-9670261-B2 | Functionalized exendin-4 derivatives | SANOFI (FR) | 2017-06-06 | — | — | US | claimed |
| US-20160220643-A1 | EXENDIN-4 DERIVATIVES AS DUAL GLP1/GLUCAGON AGONISTS | SANOFI (FR) | 2016-08-04 | — | — | US | claimed |
| US-9365632-B2 | Exendin-4 derivatives as dual GLP1/glucagon agonists | SANOFI (FR) | 2016-06-14 | — | — | US | claimed |
| EP-2934566-A1 | EXENDIN-4 DERIVATIVES AS DUAL GLP1/GIP OR TRIGONAL GLP1/GIP/GLUCAGON AGONISTS | SANOFI (FR) | 2015-10-28 | — | — | EP | claimed |
| EP-2906595-A1 | EXENDIN-4 DERIVATIVES AS DUAL GLP1/GLUCAGON AGONISTS | SANOFI (FR) | 2015-08-19 | — | — | EP | claimed |
| US-20140221281-A1 | DUAL GLP1/GIP OR TRIGONAL GLP1/GIP/GLUCAGON AGONISTS | SANOFI (FR) | 2014-08-07 | — | — | US | claimed |
| US-20140213513-A1 | Exendin-4 Derivatives as dual GLP1/GIP or trigonal GLP1/GIP/Glucagon Agonists | SANOFI (FR) | 2014-07-31 | — | — | US | claimed |
| WO-2014096145-A1 | EXENDIN-4 DERIVATIVES AS DUAL GLP1/GIP OR TRIGONAL GLP1/GIP/GLUCAGON AGONISTS | SANOFI (FR) | 2014-06-26 | — | — | WO | claimed |
| WO-2014056872-A1 | EXENDIN-4 DERIVATIVES AS DUAL GLP1/GLUCAGON AGONISTS | SANOFI (FR) | 2014-04-17 | — | — | WO | claimed |
| US-20140100156-A1 | EXENDIN-4 DERIVATIVES AS DUAL GLP1/GLUCAGON AGONISTS | SANOFI (FR) | 2014-04-10 | — | — | US | claimed |
| WO-2024003313-A1 | NEW PEPTIDES AS SELECTIVE IL-23 RECEPTOR ANTAGONISTS | SANOFI (FR) | 2024-01-04 | — | — | WO | disclosed |
| US-10758592-B2 | Exendin-4 derivatives as dual GLP1/glucagon agonists | SANOFI (FR) | 2020-09-01 | — | — | US | disclosed |
| US-10253079-B2 | Functionalized Exendin-4 derivatives | SANOFI (FR) | 2019-04-09 | — | — | US | disclosed |
| EP-3400957-A1 | FUNCTIONALIZED EXENDIN-4 DERIVATIVES | Sanofi (FR) | 2018-11-14 | — | — | EP | disclosed |
| EP-2934567-B9 | EXENDIN-4 DERIVATIVES AS DUAL GLP1/GIP- OR TRIGONAL GLP1/GIP/GLUCAGON AGONISTS | SANOFI SA (FR) | 2018-08-22 | — | — | EP | disclosed |
| US-20180185450-A1 | EXENDIN-4 DERIVATIVES AS DUAL GLP1/GLUCAGON AGONISTS | SANOFI (FR) | 2018-07-05 | — | — | US | disclosed |
| EP-2934567-B1 | EXENDIN-4 DERIVATIVES AS DUAL GLP1/GIP- OR TRIGONAL GLP1/GIP/GLUCAGON AGONISTS | SANOFI SA (FR) | 2018-05-09 | — | — | EP | disclosed |
| US-9745360-B2 | Dual GLP1/GIP or trigonal GLP1/GIP/glucagon agonists | SANOFI (FR) | 2017-08-29 | — | — | US | disclosed |
| EP-2906595-B1 | EXENDIN-4 DERIVATIVES AS DUAL GLP1/GLUCAGON AGONISTS | SANOFI SA (FR) | 2017-08-16 | — | — | EP | disclosed |
| US-20170216406-A1 | FUNCTIONALIZED EXENDIN-4 DERIVATIVES | SANOFI (FR) | 2017-08-03 | — | — | US | disclosed |
| US-9670261-B2 | Functionalized exendin-4 derivatives | SANOFI (FR) | 2017-06-06 | — | — | US | disclosed |
| US-20160220643-A1 | EXENDIN-4 DERIVATIVES AS DUAL GLP1/GLUCAGON AGONISTS | SANOFI (FR) | 2016-08-04 | — | — | US | disclosed |
| US-9365632-B2 | Exendin-4 derivatives as dual GLP1/glucagon agonists | SANOFI (FR) | 2016-06-14 | — | — | US | disclosed |
| EP-2934569-A1 | EXENDIN-4 DERIVATIVES | SANOFI (FR) | 2015-10-28 | — | — | EP | disclosed |
| EP-2934567-A1 | FUNCTIONALIZED EXENDIN-4 DERIVATIVES | SANOFI (FR) | 2015-10-28 | — | — | EP | disclosed |
| EP-2934568-A1 | DUAL GLP1/GIP OR TRIGONAL GLP1/GIP/GLUCAGON AGONISTS | SANOFI (FR) | 2015-10-28 | — | — | EP | disclosed |
| US-20140221281-A1 | DUAL GLP1/GIP OR TRIGONAL GLP1/GIP/GLUCAGON AGONISTS | SANOFI (FR) | 2014-08-07 | — | — | US | disclosed |
| US-20140206608-A1 | Exendin-4 Derivatives | SANOFI (FR) | 2014-07-24 | — | — | US | disclosed |
| US-20140206609-A1 | Functionalized Exendin-4 Derivatives | SANOFI (FR) | 2014-07-24 | — | — | US | disclosed |
| WO-2014096148-A1 | FUNCTIONALIZED EXENDIN-4 DERIVATIVES | SANOFI (FR) | 2014-06-26 | — | — | WO | disclosed |
| WO-2014096149-A1 | Exendin-4 Derivatives | SANOFI (FR) | 2014-06-26 | — | — | WO | disclosed |
| WO-2014096150-A1 | DUAL GLP1/GIP OR TRIGONAL GLP1/GIP/GLUCAGON AGONISTS | SANOFI (FR) | 2014-06-26 | — | — | WO | disclosed |
| US-20140100156-A1 | EXENDIN-4 DERIVATIVES AS DUAL GLP1/GLUCAGON AGONISTS | SANOFI (FR) | 2014-04-10 | — | — | US | disclosed |
| US-20140100156-A1 | EXENDIN-4 DERIVATIVES AS DUAL GLP1/GLUCAGON AGONISTS | SANOFI (FR) | 2014-04-10 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (10 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20140206608-A1 | Exendin-4 Derivatives | GLP1R, MC4R, NPY4R | EPHA2 2950/4885USP2 4113/4885CYP3A4 519/4885 |
| US-20180185450-A1 | EXENDIN-4 DERIVATIVES AS DUAL GLP1/GLUCAGON AGONISTS | GLP1R, GIPR, MC4R | EPHA2 3234/4885USP2 3759/4885CYP3A4 590/4885 |
| US-20170216406-A1 | FUNCTIONALIZED EXENDIN-4 DERIVATIVES | GLP1R, NPY4R, MC4R | EPHA2 1350/4885USP2 4369/4885CYP3A4 391/4885 |
| US-10758592-B2 | Exendin-4 derivatives as dual GLP1/glucagon agonists | GLP1R, GIPR, MC4R | EPHA2 3234/4885USP2 3759/4885CYP3A4 590/4885 |
| US-20140206609-A1 | Functionalized Exendin-4 Derivatives | GLP1R, NPY4R, MC4R | EPHA2 1350/4885USP2 4369/4885CYP3A4 391/4885 |
| US-20140213513-A1 | Exendin-4 Derivatives as dual GLP1/GIP or trigonal GLP1/GIP/Glucagon Agonists | GLP1R, GIPR, GCGR | EPHA2 2329/4885USP2 3743/4885CYP3A4 1370/4885 |
| US-10253079-B2 | Functionalized Exendin-4 derivatives | GLP1R, NPY4R, MC4R | EPHA2 1350/4885USP2 4369/4885CYP3A4 391/4885 |
| US-20160220643-A1 | EXENDIN-4 DERIVATIVES AS DUAL GLP1/GLUCAGON AGONISTS | GLP1R, GIPR, MC4R | EPHA2 3234/4885USP2 3759/4885CYP3A4 590/4885 |
| US-20140100156-A1 | EXENDIN-4 DERIVATIVES AS DUAL GLP1/GLUCAGON AGONISTS | GLP1R, GIPR, MC4R | EPHA2 3234/4885USP2 3759/4885CYP3A4 590/4885 |
| US-20140221281-A1 | DUAL GLP1/GIP OR TRIGONAL GLP1/GIP/GLUCAGON AGONISTS | GLP1R, GIPR, GCGR | EPHA2 2996/4885USP2 3431/4885CYP3A4 1442/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.